The FDA’s ISTAND program is moving organ-on-chip systems closer to qualified “drug development tools,” with Emulate’s liver-chip approach highlighted as a key example of progress. The coverage describes how animal testing reduction policies and NAM validation expectations are driving the transition toward human-relevant models in preclinical safety. In a cited communications medicine study, Emulate reported the Liver-Chip predicted drug-induced liver injury with 87% sensitivity and 100% specificity, outperforming comparable animal models. The result helped support an ISTAND Letter of Intent submission, and the item frames organ-on-chip qualification as an inflection point for developers seeking regulatory-usable data. The development also points to a broader standardization and acceptance challenge: qualification depends on context of use and robust evidence that regulators can interpret within review processes. For industry stakeholders, the update signals that organ-on-chip vendors will need to sustain data rigor aligned with FDA expectations while sponsors must integrate NAM outputs into development plans and dossiers.